A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be used to treat the cytopenia associated with myelodysplastic syndrome (MDS). Previously, we identified HLA-DR15, younger age, and shorter duration of red cell transfusion dependence as pretreatment variables that correlate significantly with a response. Using these pretreatment variables we have devised a simple method to prospectively identify patients with low or high probabilities of response to immunosuppression. The ability of this system to predict response was confirmed in a separate cohort of 23 patients with MDS treated with immunosuppression.
Saunthararajah
Yogen
Y
University of Illinois at Chicago, MBRB rm3150 (MC734), 900 S Ashland Ave, Chicago, IL 60607,USA. yogen@uic.edu
Nakamura
Ryotaro
R
Wesley
Robert
R
Wang
Qiong J
QJ
Barrett
A John
AJ
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015331:Cohort Studies; D016572:Cyclosporine / Q000627:therapeutic use; D006684:HLA-DR Antigens / Q000097:blood; D059810:HLA-DR Serological Subtypes; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016015:Logistic Models; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C106559:HLA-DR15 antigen; D007166:Immunosuppressive Agents; D016572:Cyclosporine